GlassScriptPhysician profile
Ruaa Y Al Ward
NPI 1629482716
$14,883.92
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.93 · 2023: $269 · 2024: $54.63 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,288 · Honoraria: $6,473 · Travel and Lodging: $655 · Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,288.43 |
| Honoraria | $6,473.00 |
| Travel and Lodging | $655.00 |
| Food and Beverage | $419.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $7,370.73 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $7,157.01 | 2023-2025 | Recorlev |
| Amgen INC. | $64.23 | 2024-2025 | Evenity, Prolia |
| Radius Health, INC. | $64.08 | 2022-2023 | Tymlos |
| Ipsen Biopharmaceuticals, INC | $33.24 | 2022-2023 | Somatuline Depot |
| Antares Pharma, INC. | $22.68 | 2024 | Xyosted |
| Amryt Pharma Holdings LTD | $20.81 | 2023 | Mycapssa |
| Novo Nordisk INC | $20.15 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.92 | 2023 | Crysvita |
| Halozyme INC | $19.32 | 2023 | |
| Alvogen INC | $17.73 | 2023 | Teriparatide |
| Chiesi USA, INC. | $17.71 | 2024 | Mycapssa |
| Recordati_rare_diseases_inc. | $14.52 | 2023 | Isturisa |
| Ascensia Diabetes Care US INC. | $14.36 | 2025 | |
| Lilly USA, LLC | $13.83 | 2023 | Mounjaro, Trulicity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $13.60 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruaa Al Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.